Title

Antibody-dye conjugate detects epidermal growth factor receptor expression in high-graded gliomas: a feasibility study for fluorescence-guided resection

Authors

Quan Zhou, PhD1, 2, Johana C. M. Vega Leonel, PhD1, Michelle R. Santoso, BS3, Christy Wilson, PhD1, Nynke S. van den Berg, PhD2, Carmel T. Chan, PhD4, Muna Aryal, PhD4, Hannes Vogel, MD5, Romain Cayrol, MD, PhD5, Michael J. Mandella, PhD4, 6, Frank Schonig, BS6, Guolan Lu, PhD2, Sanjiv S. Gambhir, MD, PhD4, Michael E. Moseley, PhD4, Eben L. Rosenthal, MD2, 7, Gerald A. Grant, MD1*

Affiliations

1 Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA;
2 Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA;
3 Department of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA;
4 Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA;
5 Department of Pathology, Stanford University, Stanford, CA, USA;
6 Institute of Quantitative Health Science and Engineering, Michigan State Univ., Lansing, MI, USA;
7 Stanford Health Care, Stanford Medical Center, Stanford, CA, USA

*Correspondence:

Gerald A. Grant, MD,
Professor of Neurosurgery,
Stanford University School of Medicine,
300 Pasteur Drive, R281,
Stanford, CA, 94305

Email: ggrant2@stanford.edu
Abstract

Background: The prognosis for high-grade glioma (HGG) remains dismal and extent of resection correlates with overall survival and progression free disease. Epidermal growth factor receptor (EGFR) is a biomarker heterogeneously expressed in HGG. We assessed the feasibility of detecting HGG using near-infrared fluorescent antibody targeting EGFR.

Methods: Mice bearing orthotopic HGG xenografts with modest EGFR expression were imaged in vivo after systemic panitumumab-IRDye800 injection to assess its tumor-specific uptake macroscopically over 14 days, and microscopically ex vivo. EGFR immunohistochemical staining of 59 tumor specimens from 35 HGG patients during was scored by pathologists and expression levels were compared to that of mouse xenografts.

Results: Intratumoral distribution of pan800 correlated with near-infrared fluorescence and EGFR expression. Fluorescence distinguished tumor cells with 90% specificity and 82.5% sensitivity. Target-to-background ratios peaked at 14 hours post panitumumab-IRDye800 infusion, reaching 19.5 in vivo and 7.6 ex vivo, respectively. Equivalent or higher EGFR protein expression compared to the mouse xenografts was present in 77.1% HGG patients. Age, combined with IDH-wildtype cerebral tumor, was predictive of greater EGFR protein expression in human tumors.

Conclusion: Tumor specific uptake of pan800 provided remarkable contrast and a flexible imaging window for fluorescence-guided identification of HGGs despite modest EGFR expression.

(Word count: 199)

Running title: Pan800 detects modest EGFR protein expression for imaging HGG

Key words: epidermal growth factor receptor; fluorescence imaging; high-grade glioma; modest protein expression; orthotopic mouse model; panitumumab-IRDye800; surgical guidance
Introduction

High-grade gliomas (HGGs) are the most common primary malignant brain tumors in adults and the leading cause of cancer-related deaths in children, carrying a poor prognosis despite intensive treatments with surgery, radiotherapy, and chemotherapy.\textsuperscript{1,2} As extent of resection correlates with overall survival and progression free disease,\textsuperscript{3-5} fluorescence guided surgery that targets specific HGG biomarkers can enhance intraoperative tumor visualization and delineation of tumor margins and improve overall survival of patients.

Epidermal growth factor receptor (EGFR) is an attractive biomarker for HGG imaging. Significantly higher EGFR protein overexpression and gene amplification are more characteristic of high-grade gliomas compared to low grade gliomas, and are implicated in tumor cell migration and aggressiveness.\textsuperscript{6,7} In a fluorescence imaging study, the IRDye800CW (Ex/Em: 774/789 nm) labeled therapeutic antibody, panitumumab-IRDye800, bound to EGFR positive rat glioma cells with higher affinity than the fluorescent EGFR ligand, EGF800.\textsuperscript{8} Moreover, this fully humanized EGFR antibody has an improved safety profile compared to its chimeric counterpart, cetuximab.\textsuperscript{9,10}

A major barrier to the clinical translation of EGFR targeting imaging probes is the heterogeneity of EGFR protein expression which can vary by orders of magnitude in human HGGs.\textsuperscript{11,12} Despite a widely recognized problem in cancer research, animal imaging studies often adopt subcutaneous xenograft models with exceptionally high target expressions that poorly represent actual malignancies in the brain.\textsuperscript{12,13} This study examined the feasibility of detecting human HGGs via fluorescence imaging using panitumumab-IRDye800 in a preclinical orthotopic tumor model with only modest level of EGFR expression which was benchmarked against similar expression levels in patient HGG tissues. Since biopsies are not usually taken before resection surgeries, HGG specimens were characterized to stratify a patient population with positive EGFR protein expression that would benefit most from intraoperative targeted imaging to assist in resection.

Results

\textit{Panitumumab-IRDye800 detects EGFR protein expressed in human glioma cells in vitro}

Four human glioma cell lines, U251, H37, D2159 and D270, \textbf{Fig 1A}, expressed EGFR protein probed by a commercial EGFR antibody with immunofluorescence assay, \textbf{Fig. 1B}. NIR
fluorescent labeled EGFR antibody, panitumumab-IRDye800, detected EGFR protein expression in the same cell lines, Fig. 1C. EGFR protein was found on the cytoplasmic membrane of individual cells (Fig. 1B & 1C insets) with 293T as negative control. Cell surface EGFR expression normalized to positive control (SCC-1) was lowest in U251 cells (MFI = 44.1 ± 2.8%) among the four lines tested, Fig. 1D. Panitumumab-IRDye800 exhibited EGFR specificity and a similar level of fluorescence in U251 cells (MFI = 42.2 ± 3.6%) in immunofluorescence assays, Fig. 1E, and demonstrated high in vitro affinity (IC50 = 43.6 nM) in a competition assay, Supplementary Fig. S1. U251 was selected to establish the orthotopic brain tumor model in mice due to its modest EGFR expression in tumors and to test the feasibility of detecting HGG with panitumumab-IRDye800 in vivo.

**U251 produces contrast enhancing orthotopic HGG xenograft tumor in mice**

U251 cells implanted (arrow) in the left hemisphere of mouse brains (n = 5) were optically accessible through a glass cranial window (white box), Fig. 2A. The implant site was examined with intravital microscope on POD7 to confirm the xenograft was growing close to the brain surface (0–300µm), Fig. 2B. Intravenously injected dextran (3kDa) was confined to the lumen of the blood vessels as a vascular tracer and suggested an intact blood-brain barrier (BBB). The tumor area revealed marked hyperintense signal in T1-weighted MRI scans with gadolinium contrast on POD15, indicating a disrupted BBB to gadolinium (molecular weight: 1058 Da), and the non-enhancing region (arrowhead) within the tumor corresponding to the focus of necrosis, Fig. 2C. The average tumor volume reached 12.1 ± 1.9 mm³ with 3.5 ± 1.2 mm in the greatest dimension. Significant post contrast enhancement between tumor and normal brain was seen on T1 imaging, from 1.21 ± 0.19 to 5.64 ± 0.98 (P = .00057, n = 5), Fig. 2D. Minimal contrast (1.13 ± 0.15) was present in the tumor area on T2-weighted MRI, indicating the absence of hydrocephalus. Tumor growth was monitored for one month via bioluminescence, Fig. 2E. Exponential growth was followed for a latency period of 12 to 18 days, with 16.7 ± 1.38-fold change from POD0 to POD30, Fig. 2F. Subsequent imaging took place at the beginning of exponential growth on POD15 (arrow).

*Panitumumab-IRDye800 detects HGG in mice in vivo and ex vivo on macroscopic near-infrared fluorescence imaging*
In mice bearing contrast enhancing HGGs \((n = 5)\), intratumoral fluorescence steadily increased after panitumumab-IRDye800 injection, peaking at 14 hours, and was maintained at a high level from 12 to 18 hours before tapering off, Figure 3A. Mean fluorescence intensity (MFI) reduced to half of its 14-hour peak after 9 days, while the target-to-background ratio (TBR) reached a high point of \(19.5 \pm 1.3\) at 14 hours and kept increasing after reaching a minimum at 48 hours, indicating a faster clearance of panitumumab-IRDye800 from normal tissue than tumor, Figure 3B. In comparison, much lower panitumumab-IRDye800 accumulated in the brain of normal mice, reaching a peak at 3 hours (MFI = 54.6 ± 6.1 % compared to that of HGG bearing mice, TBR = 6.6 ± 0.6) and returned to the baseline after two weeks, Figure 3A & B. In resected organs of tumor bearing mice \((n = 5)\), panitumumab-IRDye800 was distributed in liver, lungs, kidneys and uterus (MFI > 5 times normalized to fat), Figures 3C & D. A high concentration of panitumumab-IRDye800 was found to be specifically accumulated in HGG xenografts compared to surrounding normal brains (29.4 ± 2.6 vs. 3.9 ± 1.8 normalized to fat, contrast against normal brain = 7.6 ± 1.5, \(P = 8.03 \times 10^{-8}\)), Figure 3D. Resected HGG tumors were serially bisected and the contrast between tumor pieces against normal brain ranged between 1.22 and 9.30, Figure 3E. Tumor pieces as small as 0.9 ± 0.3 mg could be readily detected on fluorescence imaging.

**Tumor biomarkers correlate with intratumoral and molecular specific uptake of panitumumab-IRDye800**

In H&E stained mouse brain sections, tumor cells were identified by their high nucleus to cytoplasm ratio, nuclear and cytoplasmic abnormal morphology, and their pleomorphism, Figure 4A. Images of immunohistochemical staining were segmented into positive and negative pixels according to staining intensity, Supplementary Fig. S2, and quantified as staining index. HGG xenograft and infiltrating tumor cells expressed a modest level of EGFR (staining index: 34.2 ± 1.9%, \(P = 7.49 \times 10^{-15}\)), Supplementary Fig. S2, and were highly proliferative (Ki-67 staining index: 66.3 ± 2.5%, \(P = 1.28 \times 10^{-15}\)) compared to surrounding normal brain (staining index: 3.6 ± 0.8% and 7.1 ± 1.3% and for EGFR and Ki-67, respectively), Figure 4A & B. Tight-junction protein at the blood-brain barrier, claudin-5 (Cldn5, brown, cytoplasmic), was reduced in the tumor core (\(P = 4.65 \times 10^{-6}\)), Supplementary Fig. S2, and elevated endothelial cell marker, erythroblast-transformation-specific related gene (ERG, magenta, nuclear), detected hypervascularity within infiltrating tumor beds (\(P = 2.73 \times 10^{-7}\)). A diminished (29.4% of normal brain, \(P = 6.67 \times 10^{-12}\)
tight-junction protein per unit of vasculature (Cldn5/ERG) was found to be consistent with the compromised integrity of the BBB on contrast enhancing MRI. Intratumoral delivery of panitumumab-IRDye800 in near-infrared fluorescence microscopic images in areas of open BBB allowed antibody-sized molecules to cross. Furthermore, a correlation (Pearson correlation coefficient \( r = 0.88, P = 2.76 \times 10^{-9} \)) between fluorescence intensity, Fig. 4C, and EGFR immunoreactivity, Fig. 4A, validated molecular specific binding of panitumumab-IRDye800. Minimal panitumumab-IRDye800 delivery was detected in normal brain characterized by a normal BBB and resulted in high contrast (TBR = 9.1 \pm 1.7). NIR fluorescence from panitumumab-IRDye800 was able to detect tumor at 90% specificity and 83% sensitivity (area under the curve = 0.93), Fig. 4D.

**EGFR protein is commonly expressed in a variety of human high-grade gliomas**

To assess the potential of detecting EGFR with panitumumab-IRDye800 on imaging in HGG patients, EGFR protein expression was immunohistochemically characterized in human HGG tissues. 59 HGG tissue samples from a total of 35 (2.9%) patients were included in the study, Supplementary Table 1, with an even split between the genders (M/F = 17/18). EGFR protein immunohistochemistry (IHC) reactivity was heterogeneous in HGG and was scored (0, 1+, 2+, 3+ and 4+) by two board-certified neuropathologists, Fig. 5A. 27 (77.1%) of the 35 patients expressed EGFR protein at levels either equivalent (1+ & 2+ staining index: 18 – 49%) or above (3+ & 4+ staining index: 50-97%) that in mouse HGG xenografts (staining index: 19 – 42%), Fig. 5B. HGG tissues from nine patients also contained normal brain structures (e.g. choroid plexus and cerebellum) with little, if any, non-specific EGFR immunoreactivity. As a biomarker, EGFR protein expression distinguished human HGG tumors against normal brain with high specificity (89%) and sensitivity (77%) at 18.3% cutoff IHC staining index (likelihood ratio = 6.9), Fig. 5C. A majority of patients in various HGG disease subgroups expressed positive EGFR (anaplastic ependymoma, 100%; glioblastoma, 85%; atypical teratoid rhabdoid tumor, 83%; and diffuse midline glioma, 67%), Fig. 5D. A substantial number of these patients (anaplastic ependymoma and ATRT, 50%; diffuse midline glioma, 33%; and glioblastoma, 15%) expressed EGFR at a modest level (IHC score: 1+ and 2+) comparable to that found in the mouse xenografts. Two cases of medulloblastoma in this study expressed no EGFR. 60% of less common HGG diagnoses (grouped as “Other”) expressed positive EGFR. These results suggest that a large number of HGG
patients are expressing EGFR equal to or above the level detectable by panitumumab-IRDye800 imaging and could potentially benefit from fluorescence image-guided surgery.

**Clinical features of EGFR positive HGG patients**

Since patients with positive EGFR protein expression are more likely to benefit from EGFR-targeted fluorescence imaging, the focus herein was to identify patient characteristics or tumor features associated with positive EGFR protein expression. Of the 35 patients, 3 (15.8% of the 19 with molecular diagnosis) had EGFR gene amplification while 27 (77.1%) presented positive EGFR protein expression, **Fig. 5C**. These tumors were also stratified by IDH and tumor protein 53 (TP53) mutations to determine the influence of these mutations on the molecular profile of a given tumor. Clinical characteristics of patients with and without EGFR protein expression, are shown in **Table 1**. Patients with positive EGFR protein expression were older at diagnosis (median 24 versus 5 y, \( P = .0059 \)), had tumors located more frequently in the cerebral hemisphere (74% vs. 37.5%, \( P = .019 \)) and were more likely to be IDH wildtype (94% vs. 0%, \( P = .0048 \)). Over two thirds (69.2%) of pediatric patients (age < 18 y) had HGGs that expressed detectable EGFR protein on IHC. Differences in gender, tumor size, classification, WHO grade, aggressiveness (Ki-67 proliferation index) and recurrence history were not observed between the two groups; the incidence of TP53 mutation and EGFR gene amplification were also similar.

**Discussion**

Intratumoral and intertumoral EGFR expressions in HGGs are known to be heterogeneous.\(^\text{14}\) Many preclinical imaging studies were conducted on subcutaneous implants with monolithically highly positive expression of the molecular target of interest or a small number of specific patient-derived xenografts without relating their target expression level with the larger patient population. In this preclinical study, U251 cells were specifically chosen, from in vitro immunofluorescence assays, to establish the orthotopic brain tumor model in order to assess the imaging performance of panitumumab-IRDye800 in a challenging yet realistic environment where EGFR expression in tumors is more modest. As 77.1% of all human HGG tissues tested expressed EGFR at equal or higher levels, it is reasonable to believe that panitumumab-IRDye800 would be able to detect them *in vivo* as well given the right conditions.
The fluorescence signal in mouse brain tumors reached its peak at 14 hours after systemic panitumumab-IRDye800 injection. The time frame of 12 to 18 hours after panitumumab-IRDye800 infusion at this particular dose is promising for clinical translation of fluorescence guided surgery, since patients can be infused with the imaging agent on the day before surgery.\textsuperscript{10,15} This is a favorable window for imaging and gives enough time for observation of potential adverse effects. In comparison, FDA (U.S.) approved intraoperative optical imaging agent for glioma surgery, 5-ALA,\textsuperscript{16} is administered orally 2 to 4 hours before anesthesia, which can be logistically challenging to align clinical workflow with the more narrow optimal imaging window. The prolonged high TBR measured over two days can better accommodate changes in clinical workflow. In vivo imaging would be less than ideal after 48 hours, since by then, overall fluorescence intensity will have dropped significantly despite TBR continuing to increase due to faster clearing of non-specific panitumumab-IRDye800 binding.

The EGFR specific distribution of panitumumab-IRDye800 was associated with increased vasculature density and reduced BBB tight junction protein expression in contrast enhancing HGG xenografts in mice. This result was consistent with a previous clinical study where intratumoral uptake of cetuximab-IRDye800CW was observed in contrast-enhancing HGGs in two patients, but not in a third patient with an astrocytoma that on MRI also did not demonstrate any contrast enhancement.\textsuperscript{17} Taken together, these results suggest that compromised BBB integrity, indicated by contrast enhancing tumor on MRI with small molecule gadolinium, may predict intratumoral delivery of antibody-sized molecules, although further work is needed to validate this finding and elucidate the specific mechanism that may be involved in this phenomenon.

The advantage of panitumumab-IRDye800 is that this agent, due to its targeting specificity, could selectively bind to a tumor-specific biomarker of HGGs. When tested in the same animal model, panitumumab-IRDye800 demonstrated over 10% higher specificity for tumor and 30% higher comprehensive TBR than those of 5-ALA.\textsuperscript{18} As an imaging probe for fluorescence-guided surgery, panitumumab-IRDye800 could potentially outperform 5-ALA which suffers from limited imaging contrast and low negative predicting value (16.7% for HGG).\textsuperscript{19} Distribution of panitumumab-IRDye800 in resected tumor tissues could also have potential therapeutic implications such as monoclonal antibody delivery for targeted therapy although efficacy studies are beyond the scope of this study.
Population subgroups depending on intrinsic factors such as age, gender and ethnicity are commonly and intentionally included in efficacy and safety evaluation of clinical trial outcomes.\textsuperscript{20} However, patients in HGG disease subgroups with lower incidence rates but at equally high-risk, for whom effective therapeutic concepts are desperately needed, tend to be underrepresented in clinical brain imaging studies.\textsuperscript{17,21,22} As the most frequent malignant brain tumor in adults, glioblastoma accounts for 45-50\% of all primary malignant brain tumors and occurs 30 times as frequently as anaplastic oligodendroglioma.\textsuperscript{23} On the other hand, ATRT and diffuse midline glioma are rarely seen in adults but account for 10\% and 20\% of all pediatric primary tumors, respectively.\textsuperscript{24,25} The variable clinical outcome of anaplastic ependymomas in both adults and children primarily depends on the extent of surgical resection and molecular group, pointing to the clinical relevance of molecular classification.\textsuperscript{26} Ongoing clinical trials for fluorescence guided surgery of brain tumors using EGFR antibody or affibody (NCT03510208, NCT02901925 and NCT04085887) indicate the active exploration of molecular targeting strategy for detecting gliomas in both adults and children. Our preliminary findings on the frequent presence (\textgreater{} 50\%) of EGFR protein expression across multiple HGG disease subgroups are encouraging for including patients with broader age groups and diverse HGG subtypes (such as anaplastic ependymoma, ATRT and diffuse midline glioma, which predominate in children) in future clinical trials for imaging and antibody treatment therapy.

Achieving satisfactory intraoperative imaging performance using open-field optical imaging instruments has been challenging despite the presence of adequate \textit{in vivo} and \textit{ex vivo} imaging contrast in preclinical studies where closed-field fluorescence devices were used for imaging probe development.\textsuperscript{27} FDA-approved optical imaging devices vary in dynamic range and detection sensitivity, and are subject to a complex lighting environment of the operating room and clinical workflow constraints. The Pearl Triology imaging platform for this preclinical study has been used in various clinical trials for fluorescence-guide surgery to evaluate fluorescence signal of \textit{ex vivo} patient tissues in the operating room.\textsuperscript{15,28,29} Thus the \textit{ex vivo} tissue detection sensitivity (0.9mg) in the mouse model can be a realistic indication of imaging performance in the operating room under similar conditions. The high contrast (TBR = 7.6 \pm 1.5) measured in resected tumor tissues is also encouraging for the clinical application of an intraoperative pathological assessment of tumor margins. Testing tumor imaging agents in preclinical studies under lighting conditions which
mimic the operative microscope or ambient lighting and with other imaging instruments would be very valuable for further evaluation of their translational potential.

In conclusion, significant imaging contrast was observed 14 hours after systemic panitumumab-IRDye800 administration in HGG xenografts with modest EGFR protein expression. Both target and tumor specific probe uptake was confirmed microscopically. In the majority of patient HGG tissues, EGFR protein expression levels were equivalent to or higher compared to that in the preclinical model, suggesting their detectability with intraoperative EGFR targeted imaging by panitumumab-IRDye800. Older patients with IDH-wildtype cerebral hemisphere tumors tend to express greater levels of EGFR protein. These findings demonstrate the feasibility to employ an EGFR-targeting antibody for fluorescence-guided surgery of HGGs, as well as the utility of clinical profiling in stratification of HGG patients most likely to benefit from antibody-based imaging strategies.

**Methods**

**Patients**

This single-institution study was approved by the Stanford University Institutional Review Board (protocol #12625), and informed consent was obtained from all participants and/or their legal guardians. All experiments were performed in accordance with relevant guidelines and regulations. Central pathology review by the Stanford University Department of Pathology followed the 2016 WHO criteria. A total of 1197 patients were identified in the Stanford University archives with a primary diagnosis of HGG (WHO grade III or IV) between 2006 and 2019. 5% of patients (n = 60) were randomly included from HGG disease subtypes. Cases with either scant tissue or incomplete medical records were excluded, resulting in the 35 patients in the study. Two board-certified pathologists reviewed hematoxylin and eosin (H&E) slides to outline regions of viable tumor and normal brain. Peripheral cases and those with scant tissues (size < 1mm) were excluded.

**Cells**

Human glioma-derived tumorigenic cell lines, U251 (luc+, from Dr. Lawrence Recht, Stanford University), H37, D2159 and D270 (from Dr. Vidya Chandramohan, Duke University) were maintained in improved MEM zinc option medium (Gibco) as previously described. Head-and-neck squamous cell carcinoma (SCC-1, University of Michigan) and human embryonic kidney
cells (293T, ATCC) were positive and negative controls for EGFR expression, respectively. All cultures were routinely subjected to mycoplasma testing and only used for experiments when confirmed negative. Routine short tandem repeat analysis was performed using the Geneprint 10 system (Promega) to ensure cell line identity. Growth and morphology were observed with bright field (Evos XL Core, Life Technologies) and phase contrast (BZ-X710, Keyence).

**Immunofluorescence analysis**

Cells were fixed on glass slides in 4% paraformaldehyde for 15 min followed by one hour blocking (2% horse serum and 5% goat serum diluted in 1% BSA). They were incubated overnight at 4°C with either a commercial unlabeled EGFR antibody (1:2.5, RM-2111-RQ, rabbit-anti-human, Thermo Scientific) followed by secondary antibody (Alexa Fluor® 594, Invitrogen) in blocking buffer for one hour at room temperature, or a NIR-labeled human EGFR antibody, panitumumab-IRDye800 (5nM, Leidos Biomedical Research Center, Frederick, MD). Slides were counterstaining with 4', 6-diamidino-2-phenylindole (DAPI, 300 nM, Invitrogen), and imaged using a Zeiss LSM710 confocal fluorescence microscope or a custom-built fluorescence microscope (Leica). Mean fluorescence intensities (MFIs) from 10 cells per image in five images were normalized to that of the positive control (SCC-1) using Image J (v1.52p).

**Binding Competition**

U251 cells were incubated with 5nM panitumumab-IRDye800 and unlabeled panitumumab in serial dilutions (0.005nM – 5μM) overnight at 4 °C, in triple replicates. Fluorescent microscopic images were taken in five random field of views and MFIs from 10 cells per image was quantified with ImageJ (1.52p). Competitive binding curve was fitted to a logistic function equation for single-site binding $Y = \text{Bottom} + \frac{(\text{Top} - \text{Bottom})}{(1 + 10^{X - \text{LogIC50}})}$ where $\text{logIC50} = \log(10^{\log Ki \times (1 + [\text{Radioligand}]/[\text{HotKd}])))$, Radioligand = 5nM, HotKd = 0.12 nM. Equilibrium dissociation constant $Ki$ was determined as the half maximal inhibitory concentration (IC50) of unlabeled panitumumab that produces binding half-way between the upper and lower plateaus.

**Cranial window installation and orthotopic brain tumor mouse model**

Animal experiments were carried out in accordance with Stanford University Institutional Animal Care and Use Committee guidelines (protocol #26548), and in compliance with the ARRIVE guidelines (PLoS Bio 8(6), e1000412, 2010). Cranial window installation and orthotopic brain
tumor mouse model were established in twenty female NSG mice (005557, Jackson Laboratory) as previously described. U251 human xenografts were implanted (5 μl, 1 × 10^6 cells/ml) and optically accessible through a 6.0 mm x 4.0 mm x 0.4 mm glass cranial window. Normal mice were prepared using the same protocol as controls, with sham injection of 5 μl saline instead of tumor cells. Tumor growth was monitored via bioluminescence (IVIS Spectrum, PerkinElmer) every three days for one month. Total photon flux (photons/s) over the mouse brains was quantified in Living Image (v4.5.5, PerkinElmer). To ensure growth of tumor close to the surface of the brain for subsequent imaging experiments, on postoperative day 7 (POD7), vascular elements in brain tumors were imaged through the cranial window with a two-photon intravital microscope (Nikon) following 3 kDa fluorescein-dextran injection (10mg/ml, i.v., ThermoFisher). Excitation laser (920 nm) powers was modulated between 10 and 30 mW with depth (0–300 μm, step size = 5 μm). Image were reconstructed and analyzed with Image J (v1.52p).

**Magnetic resonance imaging**

Anesthesia was induced with 5% isoflurane and maintained with 2% isoflurane in room air and oxygen mixed at 3:1 ratio. Five HGG bearing mice were imaged in a 7 Tesla small-bore MR scanner (Bruker) with a Millipede RF coil (ExtendMR LLC) tuned to 298.06 MHz on POD15. T2-weighted images [repetition interval (TR) = 5 s, echo time (TE) = 33 ms, and echo train length = 8] were acquired without contrast injection. T1-weighted images [TR = 278 ms, TE = 2 ms] were taken before and after gadobenate dimeglumine (0.5 mmol/kg, i.v., molecular weight: 1058 Da, MultiHance). All images had 4 cm × 4 cm field of view, 0.5 mm slice thickness and 156 × 156 μm in-plane resolution.

**Near-infrared fluorescence imaging**

Tumor bearing mice (n = 5) and normal mice (n = 5) with cranial windows were imaged in intervals over a period of 14 days (starting on POD15) after receiving 20mg/kg panitumumab-IRDye800 (i.v.). Pharmacokinetics were measured as mean fluorescence intensity (MFI) and target-to-background ratio (TBR) calculated as MFI in each tumor region of interest, ROI-T, divided by MFI of normal tissue, ROI-B. Another five tumor bearing mice were sacrificed at the peak antibody-dye conjugate delivery time and MFIs of harvested organs were normalized to fat. Resected brain tumors were serial bisected into different sizes, weighed and imaged with normal brains. All images were collected in a near-infrared florescence imager (Ex/Em: 785/820 nm, Pearl
Trilogy Imaging System, LI-COR) and processed with Image Studio (v5.2, LI-COR). Mouse brains \( (n = 5) \) removed 14 hours after panitumumab-IRDye800 injection were formalin-fixed overnight and paraffin-embedded. Brain sections were rehydrated, incubated in DyLight 488 labeled tomato lectin (10 \( \mu \)g/ml, Vector Laboratories) for 30 minutes and counterstained with DAPI (300nM, Invitrogen) before they were imaged with a custom-built fluorescence microscope (Leica).\(^{31}\) MFIs were measured from 10 randomly selected cells in three views.

**Immunohistochemical analysis**

Formalin-fixed paraffin-embedded brain sections (4\( \mu \)m thick) were incubated with primary antibodies after heat mediated antigen retrieval. All immunohistochemical procedures were performed following preprogramed standard protocol on an automatized histostainer (Dako Autostainer, Agilent) with positive and negative controls in each operation. Immunoreactivity was visualization with diaminobenzidine and magenta chromogens (Dako EnVision). A staining index was calculated as the product of intensity and fraction of positive tumor cells using Aperio ImageScope (Leica).\(^{35}\) The immunoreactivity of human brain tissues were scored by two board-certified pathologists as previously described.\(^{36}\) Primary antibodies were: EGFR (prediluted, Thermo Scientific, RM-2111-RQ), Ki-67 (prediluted, Dako, GA62661-2), Claudin-5 (1:500, Thermo Scientific, 34-1600) and ERG (1:1000, Abcam, EPR3864). Secondary antibody: Envision FLEX+ rabbit (linker) (prediluted, Dako, SM805) for EGFR; no secondary antibody was used for all other antibodies.

**Statistical analysis**

Data are expressed as mean \( \pm \) standard error of the mean (SEM). Paired and unpaired t-tests (two-tailed) were performed for T1-weighted MR imaging contrast and other group comparisons, respectively. Patient characteristics were compared between EGFR positive and EGFR negative groups using a Wilcoxon rank-sum test and Pearson’s chi-square tests (GraphPad Prism 8.0) as appropriate. Significance was defined at \( P < 0.05 \).
References

1. Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. *Neuro-oncology* 17, iv1-iv62 (2015).
2. Gupta, T. & Sarin, R. Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. *The Lancet oncology* 3, 557-564 (2002).
3. Sanai, N. & Berger, M. S. Glioma extent of resection and its impact on patient outcome. *Neurosurgery* 62, 753-766 (2008).
4. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer cell* 17, 1 (2010).
5. Parker, J. J. et al. Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma. *Neuro-oncology* 15, 1048-1057 (2013).
6. Tannock, I. F. & Hickman, J. A. Limits to personalized cancer medicine. *N Engl J Med* 375, 1289-1294 (2016).
7. Pogue, B. W., Rosenthal, E. L., Achilefu, S. & van Dam, G. M. Perspective review of what is needed for molecular-specific fluorescence-guided surgery. *Journal of biomedical optics* 23, 100601 (2018).
8. Miller, S. E. et al. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. *Journal of neuro-oncology*, 1-9 (2018).
9. Hadijapanayis, C. G. & Stummer, W. 5-ALA and FDA approval for glioma surgery. *Journal of neuro-oncology* 141, 479-486 (2019).
10. Clark, L. T. et al. Increasing diversity in clinical trials: overcoming critical barriers. *Current Problems in Cardiology* 44, 148-172 (2019).
16

21 Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *The lancet oncology* 7, 392-401 (2006).

22 Senft, C. et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. *The lancet oncology* 12, 997-1003 (2011).

23 Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. *Neuro-oncology* 16, iv1-iv63 (2014).

24 Biegel, J. A. Molecular genetics of atypical teratoid/rhabdoid tumors. *Neurosurgical focus* 20, 1-7 (2006).

25 Himes, B. T., Zhang, L. & Daniels, D. J. Treatment strategies in diffuse midline gliomas with the H3K27M mutation: the role of convection-enhanced delivery in overcoming anatomic challenges. *Frontiers in oncology* 9, 31 (2019).

26 Pajtler, K. W. et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. *Cancer cell* 27, 728-743 (2015).

27 DSouza, A. V., Lin, H., Henderson, E. R., Samkoe, K. S. & Pogue, B. W. Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging. *Journal of biomedical optics* 21, 080901 (2016).

28 Hatakeyama, H. et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. *Plos one* 5, e12702 (2010).

29 Teraphongphom, N., Kong, C. S., Warram, J. M. & Rosenthal, E. L. Specimen mapping in head and neck cancer using fluorescence imaging. *Laryngoscope investigative otolaryngology* 2, 447-452 (2017).

30 Bullard, D. E., Schold Jr, S. C., Bigner, S. H. & Bigner, D. D. Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. *Journal of Neuropathology & Experimental Neurology* 40, 410-427 (1981).

31 Nishio, N. et al. Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer. *Nature communications* 10, 1-10 (2019).

32 Trivedi, S. et al. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. *Clinical Cancer Research* 22, 5229-5237 (2016).

33 Day, K. E., Sweeney, L., Kulbersh, B., Zinn, K. R. & Rosenthal, E. L. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. *Molecular Imaging and Biology* 15, 722-729 (2013).

34 Yecies, D. et al. Speckle modulation enables high-resolution wide-field human brain tumor margin detection and in vivo murine neuroimaging. *Scientific reports* 9, 1-9 (2019).

35 Torp, S., Gulati, S., Johannessen, E. & Dalen, A. Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. *J Exp Clin Cancer Res* 5, 6 (2007).

36 Strojin, T., Kos, J., Židanik, B., Golouh, R. & Lah, T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. *Clinical cancer research* 5, 559-567 (1999).
Acknowledgements

This work was supported by Emerson Collective Cancer Research Fund (GG), Stella Jones Foundation (GG), NIH R01CA190306 (ELR), S10RR026917-01 (MEM), T32CA118681 (GL) and NS069375 (Stanford Neuroscience Microscopy Service), and the Netherlands Organization for Scientific Research 019.171LW.022 (NSvdB). Institutional equipment loans were received from LI-COR Biosciences. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

Author contributions

Conception and design: QZ, ELR, GAG. Development of methodology: QZ, CW, MA, MEM, ELR and GAG. Review of the electronic medical records: QZ, HV, RC and NSvdB. Acquisition of data: QZ, JCMVL, MRS, NSvdB and CTC. Analysis and interpretation of data: all authors. Writing, review and/or revision of the manuscript: all authors. Administrative, technical, or material support: CW, NSvdB, MA, HV, GL, MJM, FS, SSG and MEM. Study supervision: HV, ELR and GAG. Final approval of the version to be published: all authors
Figure Legends

**Fig. 1** Panitumumab-IRDye800 specifically detects EGFR protein expression in human malignant glioma cells. **A**, Phase contrast (PH) microscopy images confirmed the healthy growth and expected morphology of six cell lines in vitro before EGFR immunostaining, including human xenograft glioma cell lines (D270, H37, D2159 and U251), positive control (SCC-1) and negative control (293T). *Insets*: bright field (BF) microscopic images of individual cell morphology. Fixed cells were immunostained with **B**, a commercial EGFR antibody and **C**, panitumumab-IRDye800 (pan800). *Insets*: high magnification views of plasma membrane staining on individual cells. EGFR<sub>Ab</sub>: commercial epidermal growth factor receptor antibody; DAPI: 4′,6-diamidino-2-phenylindole (nuclear stain); FL-C: fluorescence confocal microscopy. FL: fluorescence microscopy. **D**, Mean fluorescence intensity, with standard error of the mean (n = 10), of rabbit anti-human EGFR antibody and **E**, panitumumab-IRDye800, normalized to SCC-1 (as 100%, *dotted lines*).

**Fig. 2** U251 orthotopic implant produces contrast enhancing HGG xenograft intracranial tumor in mice. **A**, Photograph of U251 implanted (arrow) in mouse brain before (Left) and after (Right) cranial window (dashed box) placement in surgical field (*dotted lines*) on POD0. A: anterior; P: posterior; L: left; R: right. **B**, Maximum intensity projection (MIP) image (2 × 2 stitched tiles) across 0-300μm below cranial window 30s after intravenous injection of 3kDa fluorescein-dextran on POD7. *Yellow box*: a single-tile MIP image at implant site. **C**, T2-weighted (pre-contrast) and T1-weighted (pre- and post-contrast) MRI scans from a mouse with U251 glioma xenograft on POD15. *Arrowhead*: non-enhancing region within tumor. **D**, MRI contrast of tumor against normal (Mean ± SEM) revealed significant statistical difference (*P < 0.001) between T1-weighted images with and without contrast injection. **E**, Bioluminescence imaging (BLI) of glioma xenograft growth in mice over 30 days. **F**, Tumor size measured by bioluminescence grew exponentially after a latent period. *Dotted lines*: standard error of the mean. *Arrow*: beginning of exponential growth.

**Fig. 3** Pharmacokinetics and biodistribution of panitumumab-IRDye800 in vivo and ex vivo. **A**, In vivo near-infrared fluorescence imaging (NIRF) of mice bearing orthotopic HGG xenografts or normal mice (sham injection of saline) with cranial windows before and after panitumumab-IRDye800 injection over the period of 14 days. *Dotted boxes*: regions of interest (ROI) for mean
fluorescence intensity (MFI) and target-to-background ratio (TBR) measurements (T: tumor; B: background). B, Pharmacokinetics of panitumumab-IRDye800 in normal and HGG bearing mice, with standard error of the mean. Red and blue: peak values and corresponding time points for HGG and normal mice, respectively. C, NIRF images and corresponding photos of organs removed from HGG xenograft-bearing mice at 14 hours post panitumumab-IRDye800 injection. Arrows: HGG xenograft. D, Biodistribution in resected organs was quantified as MFIs (± SEM) normalized to that of fat, *P < 0.001 (n = 5) between normal brain and HGG. E, NIRF images and corresponding photos of serial bisected HGG tumor pieces and normal brain resected from mouse brains 14 hours post panitumumab-IRDye800 injection. TBR: MFI of each HGG tissue piece divided by MFI of normal brain (TBR of normal brain is set to 1.0 for each mouse).

Fig. 4 Tumor biomarkers and microscopic NIRF imaging of panitumumab-IRDye800 in HGG xenograft. A, Histology (H&E) and immunohistochemistry staining of 4µm sections of HGG xenograft bearing mouse brains 14 hours post panitumumab-IRDye800 injection. EGFR: epidermal growth factor receptor; Ki-67: nuclear protein associated with cellular proliferation; Cldn5: tight junction protein, claudin-5; ERG: erythroblast-transformation-specific related gene (a vascular endothelial marker). Red boxes: primary HGG core and normal brain margin (black dotted line); Blue boxes: HGG cells infiltrating normal brain; Arrows: blood vessels; arrowheads: infiltrating HGG tumor cells. B, IHC staining index (left Y axis) and Cldn5/ERG ratio (right Y axis, blue) of tumor areas (n = 16) and normal brains (n = 10), respectively (*P < 0.001). C, NIRF microscopic imaging of intratumoral uptake of panitumumab-IRDye800 (pan800, green) in HGG mouse brain sections in the same field of view as A. D, Fluorescence intensity of panitumumab-IRDye800 fluorescence distinguishes tumor from normal brain in C with 90% specificity and 83% sensitivity. AUC: area under the curve; ROC: receiver operating characteristic.

Fig. 5. EGFR expression across human high-grade gliomas. A, Representative microscopic images of EGFR IHC staining scored as 0, 1+, 2+, 3+ and 4+ by neuropathologists on human HGG and normal brain tissue sections. H&E: corresponding histology staining of each tissue. MB: medulloblastoma; GBM: glioblastoma multiforme; ATRT: atypical teratoid rhabdoid tumor; AE: anaplastic ependymoma; DMG: diffuse midline glioma. B, EGFR IHC staining index quantified from HGG patient tissues in A. C, EGFR distinguished human HGG tumor from normal brain as a biomarker in B with 89% specificity and 77% sensitivity. AUC: area under the curve; ROC:
receiver operating characteristic. D. Percentage of patients with EGFR positive expression (scored 1+ to 4+) in HGG disease subtypes. GBM ($n = 13$), AE ($n = 6$), ATRT ($n = 6$), DMG ($n = 3$), MB ($n = 2$) and other: anaplastic astrocytoma (4+, $n = 1$), pleomorphic glial neoplasm (4+, $n = 1$), anaplastic oligodendroglioma (2+, $n = 1$), ganglioneuroblastoma (0, $n = 1$) and anaplastic ganglioglioma (0, $n = 1$).
Table 1. Patient Demographics

|                      | EGFR –ve (n = 8) | EGFR +ve (n = 27) | P value |
|----------------------|------------------|-------------------|---------|
| Age, y               |                  |                   | .0059b  |
| Mean (SD)            | 5 (5)            | 24 (23)           |         |
| Median               | 5                | 15                |         |
| Q1, Q3               | 1, 9             | 6, 44             |         |
| Range                | 0–12             | 1–68              |         |
| Sex                  |                  |                   | .13b    |
| F                    | 6 (75%)          | 12 (44%)          |         |
| M                    | 2 (25%)          | 15 (56%)          |         |
| Tumor size, cm       |                  |                   | .093a   |
| Mean (SD)            | 6.6 (2.8)        | 4.6 (1.8)         |         |
| Median               | 5.7              | 5                 |         |
| Q1, Q3               | 4.3, 8.5         | 3.6, 5.4          |         |
| Range                | 3.8–11.2         | 1.0–8.7           |         |
| Location             |                  |                   | .019b   |
| Cerebral hemisphere  | 3 (37.5%)        | 20 (74%)          |         |
| Posterior fossa      | 4 (50%)          | 2 (7%)            |         |
| Thalamus, ventricle & spinal cord | 1 (12.5%) | 5 (19%) |         |
| Histological grading |                  |                   | .33b    |
| WHO Grade III        | 1 (12.5%)        | 8 (30%)           |         |
| WHO Grade IV         | 7 (87.5%)        | 19 (70%)          |         |
| Tumor classification |                  |                   | .20b    |
| Diffuse astrocytic and oligodendroglialc | 3 (37.5%) | 15 (56%) |         |
| Embryonald           | 4 (50%)          | 5 (19%)           |         |
| Ependymal, neuronal and others  | 1 (12.5%) | 7 (26%) |         |
| Tumor medical history|                  |                   | .68b    |
| De novo              | 6 (75%)          | 22 (81%)          |         |
| Recurrent            | 2 (25%)          | 5 (19%)           |         |
| Ki-67 proliferation index, % |      |                   | .71a    |
| Mean (SD)            | 22 (21)          | 22 (16)           |         |
| Median               | 15               | 18                |         |
| Q1, Q3               | 5, 38            | 11, 33            |         |
| Range                | 1–54             | 2–59              |         |
| Molecular features   |                  |                   |         |
| IDH mutation         | 1 (100%)         | 1 (6%)            | .0048b  |
| IDH wildtype         | 0                | 15 (94%)          |         |
| IDH unknown          | 7                | 11                |         |
| T853 mutation        | 3 (50%)          | 9 (50%)           | 1.00b   |
| TP53 wildtype        | 3 (50%)          | 9 (50%)           |         |
| TP53 unknown         | 2                | 9                 |         |
| EGFR amplification   | 0                | 3 (21%)           | .26b    |
| EGFR unamplified     | 5 (100%)         | 11 (79%)          |         |
| EGFR unknown         | 3                | 13                |         |

* Wilcoxon rank-sum test; b Pearson’s chi-squared test; c glioblastoma multiforme (GBM), diffuse midline glioma (DMG), anaplastic astrocytoma, anaplastic oligodendroglioma; d medulloblastoma (MB), ganglioneuroblastoma, atypical teratoid rhabdoid tumor (ATRT); e anaplastic ependymoma (AE), anaplastic ganglioglioma, pleomorphic glial neoplasm
Figure 1
Figure 2

A

B

C

D

E

F

3kDa Dextran

POD7

POD15

T1 pre C

T1 + C

MRI Contrast

T2 pre C

POD0

POD6

POD9

POD12

POD15

POD18

POD21

POD0

POD3

POD6

POD9

POD12

POD15

POD18

POD21

POD24

POD27

POD30

Tumor Growth - BLI

latent

exponential

0 3 6 9 12 15 18 21 24 27 30

0 2 4 6 8 10 12

1.2 x 10^10

8 x 10^9

4 x 10^9

2 x 10^9

1 cm

1 2 3 4 5 6 7

400μm

200μm

3mm

4mm

2mm
Figure 3
Figure 4

A

H&E

tumor margin

HGG

infiltrated brain

normal brain

H&E

normal brain

EGFR

Ki-67

ERG & Cldn5

C

Pan800 vessel (DAB)

Pan800 vessel (DAPI)

B

IHC staining index (%)

Clnd5/ERG

Tumor

Normal

EGFR

Ki-67

Clnd5

ERG

Clnd5/ERG

D

Pan800 Detects Tumor in HGG Xenograft Ex Vivo

Specificity: 90%

Sensitivity: 83%

AUC = 0.93

Sensitivity%
Figure 5

A

| Patient | #1 | #2 | #3 | #4 | #5 | #6 |
|---------|----|----|----|----|----|----|
| EGFR IHC | ![Image](image1) | ![Image](image2) | ![Image](image3) | ![Image](image4) | ![Image](image5) | ![Image](image6) |
| IHC score: | 0 | 1+ | 2+ | 3+ | 4+ | 0 |
| Diagnosis: | MB | GBM | ATRT | AE | DMG | normal |

B

![Graph showing EGFR IHC staining index](image7)

C

![Graph showing EGFR as Biomarker for Human HGG](image8)

D

![Bar chart showing EGFR IHC score](image9)